Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancer.

Yamamoto N, Hayashi H, Planchard D, Morán T, Gregorc V, Dowell J, Sakai H, Yoh K, Nishio M, Cortot AB, Benhadji KA, Soni N, Huang J, Makris L, Cedres S.

Invest New Drugs. 2020 Apr 3. doi: 10.1007/s10637-020-00930-5. [Epub ahead of print]

PMID:
32246224
2.

Alterations in the PI3K pathway drive resistance to MET inhibitors in NSCLC harboring MET exon 14 skipping mutations.

Jamme P, Fernandes M, Copin MC, Descarpentries C, Escande F, Morabito A, Grégoire V, Jamme M, Baldacci S, Tulasne D, Kherrouche Z, Cortot AB.

J Thorac Oncol. 2020 Mar 10. pii: S1556-0864(20)30187-8. doi: 10.1016/j.jtho.2020.01.027. [Epub ahead of print] Review.

PMID:
32169477
3.

Randomized phase II trial evaluating treatment with EGFR-TKI associated with anti-estrogen in women with non-squamous advanced stage NSCLC: IFCT-1003 LADIE trial.

Mazieres J, Barlesi F, Rouquette I, Molinier O, Besse B, Monnet I, Audigier-Valette C, Toffart AC, Renault PA, Fraboulet S, Hiret S, Mennecier B, Debieuvre D, Westeel V, Masson P, Madroszyk-Flandin A, Pichon E, Cortot AB, Amour E, Morin F, Zalcman G, Moro-Sibilot D, Souquet PJ.

Clin Cancer Res. 2020 Mar 6. pii: clincanres.3056.2019. doi: 10.1158/1078-0432.CCR-19-3056. [Epub ahead of print]

PMID:
32144133
4.

Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with Stage IV non-small cell lung cancer.

Besse B, Garrido P, Cortot AB, Johnson M, Murakami H, Gazzah A, Gil M, Bennouna J.

Lung Cancer. 2020 Apr;142:63-69. doi: 10.1016/j.lungcan.2020.02.003. Epub 2020 Feb 19.

PMID:
32114283
5.

High MET Overexpression Does Not Predict the presence of MET exon 14 Splice Mutations in NSCLC: Results From the IFCT PREDICT.amm study.

Baldacci S, Figeac M, Antoine M, Descarpentries C, Kherrouche Z, Jamme P, Copin MC, Tulasne D, Nanni I, Beau-Faller M, Melaabi S, Levallet G, Quoix E, Moro-Sibilot D, Friard S, Missy P, Barlesi F, Cadranel J, Cortot AB.

J Thorac Oncol. 2020 Jan;15(1):120-124. doi: 10.1016/j.jtho.2019.09.196. Epub 2019 Oct 9.

PMID:
31605799
6.

Erratum to "Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases" [Lung Cancer 116 (February 2018) 62-66].

Gauvain C, Vauléon E, Chouaid C, Le Rhun E, Jabot L, Scherpereel A, Vinas F, Cortot AB, Monnet I.

Lung Cancer. 2019 Oct;136:159. doi: 10.1016/j.lungcan.2018.10.011. Epub 2019 Aug 14. No abstract available.

PMID:
31421927
7.

Relevance of Detection of Mechanisms of Resistance to ALK Inhibitors in ALK-Rearranged NSCLC in Routine Practice.

Jamme P, Descarpentries C, Gervais R, Dansin E, Wislez M, Grégoire V, Richard N, Baldacci S, Rabbe N, Kyheng M, Kherrouche Z, Escande F, Copin MC, Cortot AB.

Clin Lung Cancer. 2019 Jul;20(4):297-304.e1. doi: 10.1016/j.cllc.2019.02.013. Epub 2019 Feb 26.

PMID:
31147208
8.

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.

Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot AB, Mezquita L, Thai AA, Mascaux C, Couraud S, Veillon R, Van den Heuvel M, Neal J, Peled N, Früh M, Ng TL, Gounant V, Popat S, Diebold J, Sabari J, Zhu VW, Rothschild SI, Bironzo P, Martinez-Marti A, Curioni-Fontecedro A, Rosell R, Lattuca-Truc M, Wiesweg M, Besse B, Solomon B, Barlesi F, Schouten RD, Wakelee H, Camidge DR, Zalcman G, Novello S, Ou SI, Milia J, Gautschi O.

Ann Oncol. 2019 Aug 1;30(8):1321-1328. doi: 10.1093/annonc/mdz167.

PMID:
31125062
9.

Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation.

Auliac JB, Pérol M, Planchard D, Monnet I, Wislez M, Doubre H, Guisier F, Pichon E, Greillier L, Mastroianni B, Decroisette C, Schott R, Le Moulec S, Arrondeau J, Cortot AB, Gerinière L, Renault A, Daniel C, Falchero L, Chouaid C.

Lung Cancer. 2019 Jan;127:96-102. doi: 10.1016/j.lungcan.2018.11.037. Epub 2018 Nov 27.

PMID:
30642559
10.

MET amplification increases the metastatic spread of EGFR-mutated NSCLC.

Baldacci S, Kherrouche Z, Cockenpot V, Stoven L, Copin MC, Werkmeister E, Marchand N, Kyheng M, Tulasne D, Cortot AB.

Lung Cancer. 2018 Nov;125:57-67. doi: 10.1016/j.lungcan.2018.09.008. Epub 2018 Sep 11.

PMID:
30429039
11.

Extra cost of brain metastases (BM) in patients with non-squamous non-small cell lung cancer (NSCLC): a French national hospital database analysis.

Girard N, Cozzone D, de Leotoing L, Tournier C, Vainchtock A, Tehard B, Cortot AB.

ESMO Open. 2018 Sep 8;3(6):e000414. doi: 10.1136/esmoopen-2018-000414. eCollection 2018.

12.

Optimization of Routine Testing for MET Exon 14 Splice Site Mutations in NSCLC Patients.

Descarpentries C, Leprêtre F, Escande F, Kherrouche Z, Figeac M, Sebda S, Baldacci S, Grégoire V, Jamme P, Copin MC, Tulasne D, Cortot AB.

J Thorac Oncol. 2018 Dec;13(12):1873-1883. doi: 10.1016/j.jtho.2018.08.2023. Epub 2018 Sep 7.

13.

[MET exon 14 splicing sites mutations: A new therapeutic opportunity in lung cancer].

Baldacci S, Kherrouche Z, Descarpentries C, Wislez M, Dansin E, Furlan A, Tulasne D, Cortot AB.

Rev Mal Respir. 2018 Oct;35(8):796-812. doi: 10.1016/j.rmr.2018.01.011. Epub 2018 Aug 31. Review. French.

PMID:
30174236
14.

[Tumour assessment criteria for immune checkpoint inhibitors].

Wasielewski E, Cortot AB.

Rev Mal Respir. 2018 Oct;35(8):828-845. doi: 10.1016/j.rmr.2017.06.007. Epub 2018 Aug 27. Review. French.

PMID:
30166076
15.

Current and Former Smokers: Who Wants To Be Screened?

Couraud S, Greillier L, Brignoli-Guibaudet L, Lhomel C, Viguier J, Morère JF, Eisinger F, Cortot AB.

Clin Lung Cancer. 2018 Nov;19(6):493-501. doi: 10.1016/j.cllc.2018.07.001. Epub 2018 Jul 6.

PMID:
30107977
16.

Beliefs and behavior regarding e-cigarettes in a large cross-sectional survey.

Couraud S, Cortot AB, Pivot XB, Touboul C, Lhomel C, Blay JY, Eisinger F, Viguier J, Morère JF, Greillier L.

Prev Med Rep. 2018 Apr 18;10:332-336. doi: 10.1016/j.pmedr.2018.04.009. eCollection 2018 Jun.

17.

The multiple paths towards MET receptor addiction in cancer.

Duplaquet L, Kherrouche Z, Baldacci S, Jamme P, Cortot AB, Copin MC, Tulasne D.

Oncogene. 2018 Jun;37(24):3200-3215. doi: 10.1038/s41388-018-0185-4. Epub 2018 Mar 19. Review.

PMID:
29551767
18.

Perception of Lung Cancer Risk: Impact of Smoking Status and Nicotine Dependence.

Greillier L, Cortot AB, Viguier J, Brignoli-Guibaudet L, Lhomel C, Eisinger F, Morère JF, Couraud S.

Curr Oncol Rep. 2018 Mar 5;20(Suppl 1):18. doi: 10.1007/s11912-017-0650-1.

PMID:
29508085
19.

Real-life experience of ceritinib in crizotinib-pretreated ALK+ advanced non-small cell lung cancer patients.

Cadranel J, Cortot AB, Lena H, Mennecier B, Do P, Dansin E, Mazieres J, Chouaid C, Perol M, Barlesi F, Robinet G, Friard S, Thiberville L, Audigier-Valette C, Vergnenegre A, Westeel V, Slimane K, Buturuga A, Moro-Sibilot D, Besse B.

ERJ Open Res. 2018 Feb 13;4(1). pii: 00058-2017. doi: 10.1183/23120541.00058-2017. eCollection 2018 Jan.

20.

Real-life feasibility of home-based pulmonary rehabilitation in chemotherapy-treated patients with thoracic cancers: a pilot study.

Olivier C, Grosbois JM, Cortot AB, Peres S, Heron C, Delourme J, Gierczynski M, Hoorelbeke A, Scherpereel A, Le Rouzic O.

BMC Cancer. 2018 Feb 13;18(1):178. doi: 10.1186/s12885-018-4102-6.

21.

Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases.

Gauvain C, Vauléon E, Chouaid C, Le Rhun E, Jabot L, Scherpereel A, Vinas F, Cortot AB, Monnet I.

Lung Cancer. 2018 Feb;116:62-66. doi: 10.1016/j.lungcan.2017.12.008. Epub 2017 Dec 14. Erratum in: Lung Cancer. 2019 Oct;136:159.

PMID:
29413052
22.

Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors.

Baldacci S, Mazieres J, Tomasini P, Girard N, Guisier F, Audigier-Valette C, Monnet I, Wislez M, Pérol M, Dô P, Dansin E, Leduc C, Giroux Leprieur E, Moro-Sibilot D, Tulasne D, Kherrouche Z, Labreuche J, Cortot AB.

Oncotarget. 2017 Oct 9;8(62):105103-105114. doi: 10.18632/oncotarget.21707. eCollection 2017 Dec 1.

23.

Defining the "Frequent Exacerbator" Phenotype in COPD: A Hypothesis-Free Approach.

Le Rouzic O, Roche N, Cortot AB, Tillie-Leblond I, Masure F, Perez T, Boucot I, Hamouti L, Ostinelli J, Pribil C, Poutchnine C, Schück S, Pouriel M, Housset B.

Chest. 2018 May;153(5):1106-1115. doi: 10.1016/j.chest.2017.10.009. Epub 2017 Oct 17.

PMID:
29054347
24.

Factors influencing colorectal cancer screening participation rates in 2016.

Viguier J, Morere JF, Pivot X, Cortot AB, Blay JY, Touboul C, Lhomel C, Greillier L, Couraud S, Eisinger F.

Ann Oncol. 2017 Jun;28 Suppl 3:iii90-iii91. doi: 10.1093/annonc/mdx261.256. No abstract available.

25.

Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers.

Cortot AB, Kherrouche Z, Descarpentries C, Wislez M, Baldacci S, Furlan A, Tulasne D.

J Natl Cancer Inst. 2017 May 1;109(5). doi: 10.1093/jnci/djw262. Review.

PMID:
28376232
26.

Dynamic contrast-enhanced MR imaging pharmacokinetic parameters as predictors of treatment response of brain metastases in patients with lung cancer.

Kuchcinski G, Le Rhun E, Cortot AB, Drumez E, Duhal R, Lalisse M, Dumont J, Lopes R, Pruvo JP, Leclerc X, Delmaire C.

Eur Radiol. 2017 Sep;27(9):3733-3743. doi: 10.1007/s00330-017-4756-5. Epub 2017 Feb 16.

PMID:
28210799
27.

First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.

Soria JC, Tan DSW, Chiari R, Wu YL, Paz-Ares L, Wolf J, Geater SL, Orlov S, Cortinovis D, Yu CJ, Hochmair M, Cortot AB, Tsai CM, Moro-Sibilot D, Campelo RG, McCulloch T, Sen P, Dugan M, Pantano S, Branle F, Massacesi C, de Castro G Jr.

Lancet. 2017 Mar 4;389(10072):917-929. doi: 10.1016/S0140-6736(17)30123-X. Epub 2017 Jan 24. Erratum in: Lancet. 2017 Mar 4;389(10072):908.

PMID:
28126333
28.

[Cancer screening in France: 10 years of analysis of behaviours by the EDIFICE surveys].

Eisinger F, Pivot X, Greillier L, Couraud S, Cortot AB, Touboul C, Lhomel C, Blay JY, Morère JF, Viguier J.

Bull Cancer. 2017 Mar;104(3):258-266. doi: 10.1016/j.bulcan.2016.12.002. Epub 2017 Jan 18. Review. French.

PMID:
28108012
29.

Preferential Localization of MET Expression at the Invasion Front and in Spreading Cells Through Air Spaces in Non-Small Cell Lung Carcinomas.

Lapère C, Cortot AB, Grégoire V, Cockenpot V, Tulasne D, Copin MC.

Am J Surg Pathol. 2017 Mar;41(3):414-422. doi: 10.1097/PAS.0000000000000810.

PMID:
28098570
30.

MET receptor variant R970C favors calpain-dependent generation of a fragment promoting epithelial cell scattering.

Montagne R, Baranzelli A, Muharram G, Catherine L, Lesaffre M, Vinchent A, Kherrouche Z, Werkmeister E, Cortot AB, Tulasne D.

Oncotarget. 2017 Feb 14;8(7):11268-11283. doi: 10.18632/oncotarget.14499.

31.

[Osimertinib (Tagrisso®): Activity, indication and modality of use in non-small cell lung cancer].

Giroux Leprieur E, Cortot AB, Cadranel J, Wislez M.

Bull Cancer. 2016 Oct;103(10):815-821. doi: 10.1016/j.bulcan.2016.06.007. Epub 2016 Sep 15. French.

PMID:
27641462
32.

Afatinib + Cetuximab First-line in EGFR-Mutant Lung Cancer--Letter.

Cortot AB, Moro-Sibilot D, Cadranel J.

Clin Cancer Res. 2016 Apr 1;22(7):1827. doi: 10.1158/1078-0432.CCR-15-2824. No abstract available.

33.

PEA3 transcription factors are downstream effectors of Met signaling involved in migration and invasiveness of Met-addicted tumor cells.

Kherrouche Z, Monte D, Werkmeister E, Stoven L, De Launoit Y, Cortot AB, Tulasne D, Chotteau-Lelievre A.

Mol Oncol. 2015 Nov;9(9):1852-67. doi: 10.1016/j.molonc.2015.07.001. Epub 2015 Jul 15.

34.

[Systemic treatment of brain metastases from lung cancer].

Barlesi F, Spano JP, Cortot AB, Carpentier AF, Robinet G, Besse B.

Cancer Radiother. 2015 Feb;19(1):43-7. doi: 10.1016/j.canrad.2014.12.001. Epub 2015 Feb 2. Review. French.

PMID:
25656857
35.

ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice?

Girard N, Audigier-Valette C, Cortot AB, Mennecier B, Debieuvre D, Planchard D, Zalcman G, Moro-Sibilot D, Cadranel J, Barlési F.

Expert Rev Anticancer Ther. 2015 Feb;15(2):225-33. doi: 10.1586/14737140.2014.986103. Epub 2014 Nov 21. Review.

PMID:
25413260
36.

[ALK-rearranged non-small cell lung cancer: how to optimize treatment with crizotinib in routine practice?].

Audigier-Valette C, Girard N, Cortot AB, Mennecier B, Debieuvre D, Planchard D, Zalcman G, Moro-Sibilot D, Cadranel J, Barlesi F.

Bull Cancer. 2014 Sep;101(9):823-31. doi: 10.1684/bdc.2014.1976. French.

PMID:
25299566
37.

Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas.

Cortot AB, Jänne PA.

Eur Respir Rev. 2014 Sep;23(133):356-66. doi: 10.1183/09059180.00004614. Review.

38.

[Individual lung cancer screening in practice. Perspectives on the propositions from the multidisciplinary group of the Intergroupe francophone de cancérologie thoracique, the Société d'imagerie thoracique and the Groupe d'oncologie de langue française].

Girard N, Gounant V, Mennecier B, Greillier L, Cortot AB, Couraud S, Besse B, Brouchet L, Castelnau O, Ferretti GR, Frappé P, Khalil A, Lefebure P, Laurent F, Liebart S, Margery J, Molinier O, Quoix E, Revel MP, Stach B, Souquet PJ, Thomas P, Trédaniel J, Lemarié E, Zalcman G, Barlési F, Milleron B; groupe de travail multidisciplinaire de l’Intergroupe francophone de cancérologie thoracique, de la Société d’imagerie thoracique et du Groupe d’oncologie de langue française.

Rev Mal Respir. 2014 Jan;31(1):91-103. doi: 10.1016/j.rmr.2013.10.641. Epub 2014 Jan 10. French. No abstract available.

PMID:
24461451
39.

Mutation of TP53 and alteration of p14(arf) expression in EGFR- and KRAS-mutated lung adenocarcinomas.

Cortot AB, Younes M, Martel-Planche G, Guibert B, Isaac S, Souquet PJ, Commo F, Girard P, Fouret P, Brambilla E, Hainaut P, Soria JC.

Clin Lung Cancer. 2014 Mar;15(2):124-30. doi: 10.1016/j.cllc.2013.08.003. Epub 2013 Oct 26.

PMID:
24169260
40.

Identification of microRNA-based signatures for response and survival for non-small cell lung cancer treated with cisplatin-vinorelbine A ELCWP prospective study.

Berghmans T, Ameye L, Willems L, Paesmans M, Mascaux C, Lafitte JJ, Meert AP, Scherpereel A, Cortot AB, Cstoth I, Dernies T, Toussaint L, Leclercq N, Sculier JP; European Lung Cancer Working Party.

Lung Cancer. 2013 Nov;82(2):340-5. doi: 10.1016/j.lungcan.2013.07.020. Epub 2013 Aug 7.

PMID:
24007627
41.

Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.

Mazières J, Peters S, Lepage B, Cortot AB, Barlesi F, Beau-Faller M, Besse B, Blons H, Mansuet-Lupo A, Urban T, Moro-Sibilot D, Dansin E, Chouaid C, Wislez M, Diebold J, Felip E, Rouquette I, Milia JD, Gautschi O.

J Clin Oncol. 2013 Jun 1;31(16):1997-2003. doi: 10.1200/JCO.2012.45.6095. Epub 2013 Apr 22.

PMID:
23610105
42.

Relevance of an extensive follow-up after surgery for nonsmall cell lung cancer.

Gourcerol D, Scherpereel A, Debeugny S, Porte H, Cortot AB, Lafitte JJ.

Eur Respir J. 2013 Nov;42(5):1357-64. doi: 10.1183/09031936.00086712. Epub 2013 Mar 21.

43.

Bevacizumab and weekly paclitaxel for non-squamous non small cell lung cancer patients: a retrospective study.

Habib S, Delourme J, Dhalluin X, Petyt G, Tacelli N, Scherpereel A, Lafitte JJ, Cortot AB.

Lung Cancer. 2013 May;80(2):197-202. doi: 10.1016/j.lungcan.2013.01.015. Epub 2013 Feb 14.

PMID:
23414642
44.

[Castleman's disease: unusual presentation of Castleman's disease and review of literature].

Baranzelli A, Akkad R, Bouchindhomme B, Tacelli N, Delourme J, Dhalluin X, Lafitte JJ, Scherpereel A, Remy-Jardin M, Cortot AB.

Rev Pneumol Clin. 2013 Feb;69(1):55-9. doi: 10.1016/j.pneumo.2012.12.005. Epub 2013 Jan 29. Review. French.

PMID:
23374393
45.

[Should elevated beta-HCG levels be an exclusion criteria in clinical trials? A case report of paraneoplastic secretion associated with lung adenocarcinoma].

Taverne J, Delourme J, Dhalluin X, Copin MC, Scherpereel A, Lafitte JJ, Cortot AB.

Rev Pneumol Clin. 2013 Feb;69(1):36-40. doi: 10.1016/j.pneumo.2012.12.002. Epub 2013 Jan 18. French.

PMID:
23337393
46.

[Malignant pleural mesothelioma: diagnosis and treatment].

Delourme J, Dhalluin X, Cortot AB, Lafitte JJ, Scherpereel A.

Rev Pneumol Clin. 2013 Feb;69(1):26-35. doi: 10.1016/j.pneumo.2012.12.003. Epub 2013 Jan 14. Review. French.

PMID:
23333048
47.

Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway.

Cortot AB, Repellin CE, Shimamura T, Capelletti M, Zejnullahu K, Ercan D, Christensen JG, Wong KK, Gray NS, Jänne PA.

Cancer Res. 2013 Jan 15;73(2):834-43. doi: 10.1158/0008-5472.CAN-12-2066. Epub 2012 Nov 19.

48.

From randomized trials to the clinic: is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the French intergroup (IFCT) and the groupe d'Oncologie de langue francaise (GOLF).

Couraud S, Cortot AB, Greillier L, Gounant V, Mennecier B, Girard N, Besse B, Brouchet L, Castelnau O, Frappé P, Ferretti GR, Guittet L, Khalil A, Lefebure P, Laurent F, Liebart S, Molinier O, Quoix E, Revel MP, Stach B, Souquet PJ, Thomas P, Trédaniel J, Lemarié E, Zalcman G, Barlési F, Milleron B; French lung cancer screening statement taskforce; groupe d'Oncologie de langue française.

Ann Oncol. 2013 Mar;24(3):586-97. doi: 10.1093/annonc/mds476. Epub 2012 Nov 7.

49.

[EGFR inhibitors in non-small cell lung cancer: more than yesterday (but less than tomorrow)].

Cortot AB.

Rev Pneumol Clin. 2010 Dec;66(6):367-74. doi: 10.1016/j.pneumo.2010.07.017. Epub 2010 Dec 3. Review. French.

PMID:
21167447
50.

KRAS mutation status in primary nonsmall cell lung cancer and matched metastases.

Cortot AB, Italiano A, Burel-Vandenbos F, Martel-Planche G, Hainaut P.

Cancer. 2010 Jun 1;116(11):2682-7. doi: 10.1002/cncr.25014.

Supplemental Content

Loading ...
Support Center